The global Anaplastic Thyroid Cancer (ATC) drug market is anticipated to grow at a significant CAGR during the forecast period(2022-2028). The anaplastic thyroid cancer drug is an aggressive variant of thyroid cancer that affect the uncontrolled growth cell in the thyroid gland. It increases in the setting of differentiated thyroid cancers are papillary or follicular thyroid cancers. In addition, the recompense policy for chemotherapy is propelling the growth of the market. Chemotherapy treatment means that the drug enters the bloodstream and travels throughout the body to reach and break down the cancer cells. It uses anti-cancer drugs to be injected into a layer. It is often associated with external radiation treatment of anaplastic thyroid cancer and is sometimes used for other advanced cancers that do not respond to other treatments. 

The rising prevalence of anaplastic thyroid cancer and thyroid cancer is driving the ATC drug market during the forecast period. Thyroid cancer was the sixth most prevalent cancer in 2021, according to the American Society of Clinical Oncology (ASCO), with women three times more likely to develop it. Further, according to the Thyroid Cancer Survivors' Association, there were 52,890 new cases of thyroid cancer diagnosed in the US in 2020, up from 52,070 instances in 2019. Thyroid cancer-related mortalities were 2,180 in 2020, up from 2,170 in 2019, 2,060 in 2018, and 2,010 in 2017.

Impact of COVID-19 on Global Anaplastic Thyroid Cancer Drug Market

The COVID-19 has impacted the global economy due to a slowdown in the manufacturing of various industries. Anaplastic thyroid cancer drug has several impacts on the  COVID 19 such as the diagnosis has been delayed due to social distancing norms and isolation, reduced access to investigations and redeployment of staff and also treatment planning has needed to assess the risk to patients and staff of nosocomial transmission of the virus. The Anaplastic thyroid cancer diagnosis and therapies market has declined especially in the first half of 2020.  The pandemic has had an impact on how people function and how different surgical procedures are performed. The number of cancer surgeries has significantly declined during the pandemic, due to the strict guidelines by the regulatory authorities to avoid all non-emergent surgeries. The outbreak of COVID-19 has disrupted the supply of raw materials and products across the globe. 

Segmental Outlook 

The global anaplastic thyroid cancer drug market is segmented based on the product. Based on the type, the market is segmented into sorafenib, paclitaxel, and pazopanib HCL, MLN0128, everolimus, CA4 P, bevacizumab, and others. The above-mentioned segments can be customized as per the requirements. Among these, the everolimus segment is anticipated to propel the growth of the market over the forecast period. The everolimus is an anti-tumor activity in anaplastic thyroid cancer drugs. 

Global Anaplastic Thyroid Cancer Drug Market Share by Product, 2021 (%) 

The Bevacizumab Segment is Anticipated to Hold a Prominent Share in the Global Anaplastic Thyroid Cancer Drug Market

In anaplastic thyroid cancer drugs, the bevacizumab segment is a major indicator of new treatments. It represents one of the deadliest human diseases and is opposed to common treatments such as chemotherapy and radiotherapy. It evaluates a novel therapeutic approach based on the oncolytic replication-selective adenovirus dl922-947. In addition, bevacizumab enhances the oncolytic effects of dl922-947 by enhancing the spread of the virus in tumors. The results described encourages the use of the virus dl922-947 in combination with bevacizumab.

Regional Outlooks

The global anaplastic thyroid cancer drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement. The North America regional anaplastic thyroid cancer drug market is expected to hold a prominent market share due to the presence of several key market players.

Global Anaplastic Thyroid Cancer Drug Market Growth, by Region 2022-2028 

The North America Region is estimated to Hold the Major Share in the Global Anaplastic Thyroid Cancer Drug Market

North America is anticipated to hold a prominent share in the market owing to the increasing incidence of anaplastic thyroid cancer and the focus on the research and development for ATC treatment. According to the Centers for Disease Control and Prevention, every year about 35,000 women and 12,000 men suffer from thyroid cancer, and more than 1,100 women and 900 men die from the disease. In addition, in the US in 2016, an estimated 64,000 new patients were diagnosed with thyroid cancer. Further, the development of the market is attributed to the presence of reimbursement policies. In addition, the improved healthcare infrastructure is boosting the growth of the anaplastic thyroid cancer drug market in North America. 

Market Players Outlook

The major companies serving the global anaplastic thyroid cancer drug market include Novartis International AG. Pfizer Inc., Daiichi Sankyo Co. Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.  For instance,  in February 2019, Eli Lilly and Company acquired Loxo Oncology, Inc. at $8 Billion. The acquisition gives Eli Lilly access to a pipeline of research drugs such as RET inhibitors used to treat thyroid cancer. Loxo Oncology was founded in 2013 and is based in Stamford, USA.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global anaplastic thyroid cancer drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.